BioCentury
ARTICLE | Clinical News

ADV6209 regulatory update

October 17, 2016 7:00 AM UTC

Primex submitted an MAA for ADV6209 under the EU’s decentralized procedure as moderate sedation prior to therapeutic or diagnostic procedures in children ages 6 months to 17 years. France is acting as...